Human reactive-appearing « non-monomorphous » malignant disorders, such as Hodgkin's disease, T-cell-rich B-cell lymphomas and angioimmunoblastic lymphadenopathy display a peculiar and unifying characteristic, which biologically differentiates them from « monomorphous » non-Hodgkin's lymphomas. It consists in the coexistence within the pathologic tissue of a polyclonal, normal-appearing, presumed reactive cellular component, mainly composed of T-lymphocytes together with a clonal cell component constituting a minority of the pathologic mass. To explain the long-lasting coexistence of such polymorphic cell populations in the pathologic tissue of synchronous and metachronous localizations of the disease, it is hypothesized that they are interconnected by « biological interactions » which determine and sustain the pathologic process. Based on the biological characteristics of an experimental model (the follicular center cell « lymphoma » of the SJL murine strain), it is suggested that these human « non-monomorphous » malignant diseases should be regarded as a continuous spectrum of lymphoproliferative disorders sustained by a biological loop which interconnects different cell populations able to stimulate each other for growth.
Get full access to this article
View all access options for this article.
References
1.
AlisauskasR.M., PonzioN.M.: T-helper cell-specific monoclonal antibody inhibits growth of B-cell lymphomas (RCS) in syngeneic SJL/J mice.Fed. Proc., 45: 269, 1986.
2.
AlisauskasR.M., PonzioN.M.: T-helper cell-specific monoclonal antibody inhibits progressive growth of B-cell lymphomas in syngeneic SJL/J mice.Cell. Immunol., 119: 286–303, 1989.
3.
AlisauskasR.M., FriedmanC.A., PonzioN.M.: Influence of T-helper cells specific monoclonal antibody on progressive growth of B-cell lymphomas in SJL/J mice: correlation of acute treatment dosage with tumor dormancy or complete remission in long-term survivors.Cancer Commun., 2: 33–43, 1990.
4.
BoiocchiM., CarboneA., De ReV., DolcettiR.: Is the Epstein-Barr virus involved in Hodgkin's disease?Tumori, 75: 345–350, 1989.
5.
BoiocchiM., De ReV., DolcettiR., CarboneA., ScarpaA., MenestrinaF.: Association or Epstein-Barr virus with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes.Annals of Oncology, 3: 307–310, 1992.
6.
BorosL., BhaskarA.G., D'SouraJ.P.: Monoclonal evolution of angioimmunoblastic lymphadenopathy.Am. J. Clin. Pathol., 75: 856–860, 1981.
7.
BornkammG.W., SteinH., LennerK., RuggebergF., BartlesH., zur HausenH.: Attempts to demonstrate virus-specific sequences in human tumors. IV. EB viral DNA in European Burkitt lymphoma and immunoblastic lymphadenopathy with excessive plasmacytosis.Int. J. Cancer, 17: 177–181, 1976.
8.
BrownP.H., ThorbeckeG.J.: Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T-cells.J. Immunol., 135: 3572–3586, 1985.
9.
BrowneH., SmithG., BeckS., MinsonT.: A complex between the MHC class I homologue encoded by human cytomegalovirus and ã2 microglobulin.Nature (Lond.), 347: 770–772, 1980.
10.
BurgetH.-G., KvistS.: An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens.Cell, 41: 987–997, 1985.
11.
BurrichterH., HeitW., SchaadtM., KirchnerH., DiehlV.: Production of colony-stimulating factors by Hodgkin's cell lines.Int. J. Cancer, 31: 269–274, 1983.
12.
CarswellE.A., LermanS.P., ThorbeckeG.J.: Properties of reticulum cell sarcomas in SJL/J mice: II. Fate of labeled tumor cells in normal and irradiated syngeneic mice.Cell. Immunol., 23: 35–59, 1976.
13.
CollinsR.H.Jr.: The pathogenesis of Hodgkin's disease.Blood Reviews, 4: 61–68, 1990.
De KruiffR.H., BrownP.H., ThorbeckeG.J., PonzioN.M.: Characterization of SJL cell clones responsive to syngeneic lymphoma (RCS): RCS-specific clones are stimulated by activated B-cells.J. Immunol., 135: 3581–3586, 1985.
16.
Del ValM., MunchK., ReddehaseM.J., KesrinowskiU.H.: Presentation of CMV immediate-early antigen to cytolytic T-lymphocytes is selectively prevented by viral genes expressed in the early phase.Cell, 58: 305–315, 1989.
EllisT.M., McMannisJ.D., ChuaA.O., GublerU., FisherR.I.: Interleukin-1-independent activation of human T-lymphocytes stimulated by anti-CD3 and Hodgkin's disease cell line with accessory cell activity.Cell. Immunol., 116: 352–366, 1988.
FrizzeraG., MoranE.M., RappaportH.: Angioimmunoblastic lymphadenopathy: diagnosis and clinical course.Am. J. Med., 59: 803–818, 1975.
21.
FrizzeraG., KanekoY., SakuraiM.: Angioimmunoblastic lymphadenopathy and related disorders: a retrospective look in search of definition, Leukemia, 3: 1–5, 1989.
22.
HayamaT., PonzioN.M., NaglerC., VilcekJ., ThorbeckeG.J.: Ia-restricted interaction of normal lymphoid cells and SJL lymphoma (reticulum cell sarcoma) leading to lymphokine production. III. Relative roles of RCS and normal lymphoid cells in lymphokine production.J. Natl. Cancer Inst., 72: 321–331, 1984.
23.
Haran-GheraN., KatlerM., MeshoresA.: Studies on leukemia development in the SJL/J strain of mice.J. Natl. Cancer Inst., 39: 653–661, 1967.
24.
HondaM., SmithH.R., SteinbergH.D.: Studies of the pathogenesis of angioimmunoblastic lymphadenopathy.J. Clin. Invest., 76: 332–340, 1985.
25.
HsuS.M., ZhaoX.: Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies.Am. J. Pathol., 125: 221–225, 1988.
26.
KayA.B., McVieJ.G., StuartA.E., KrajeowskiA., TurnbullL.W.: Eosinophilic chemotaxis of supernatants from cultured Hodgkin's lymph node cells.J. Clin. Pathol., 28: 502–505, 1975.
27.
KaplanH.S.: Hodgkin's Disease.Harvard University Press, Cambridge, 1980.
28.
KatzI.R., Chapman-AlexanderJ., JacobsonE.B., LermanS.P., ThorbeckeG.J.: Growth of SJL/J-derived transplantable reticulum cell sarcoma as related to its ability to induce T-cell proliferation in the host. III. Studies on thymectomized and congenitally athymic SJL mice.Cell. Immunol., 65: 84–92, 1981.
29.
KatzJ.D., LebowL.T., BonavidaB.: The in vivo depletion of Vã17a+ T-cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in control of malignancy.J. Immunol., 143: 1387–1395, 1989.
30.
KatzI.R., AsofskyA., ThorbeckeG.J.: Suppression of spontaneous reticulum cell sarcoma development and of syngeneic stimulator cells by anti-mu treatment of SJL/J mice.J. Immunol., 125: 1355–1359, 1980.
31.
KleinG.: Lymphoma development in mice and humans: diversity of initiation is followed by cytogenetic evolution.Proc. Natl. Acad. Sci USA, 76: 2442–2446, 1979.
32.
KnechtH., LennertK.: History and clinical picture of lymphogranulomatosis X including (angio) immunoblastic lymphadenopathy.Schweiz. Med. Wochenschr., 111: 1108–1121, 1981.
KruegerG.R., BergholzM., BarthschH.H., FischerR., SchauerA.: Rubella virus antigen in lymphocytes of patients with angioimmunoblastic lymphadenopathy (AIL). J.Cancer Res. Clin. Oncol., 95: 87–91, 1979.
35.
KuechtH.: Angioimmunoblastic lymphadenopathy: ten years’ experience and state of current knowledge.Semin. Hematol., 26: 208–215, 1989.
36.
LandH., ParadaL.F., WeinbergR.A.: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.Nature (Lond.), 304: 596–602, 1983.
37.
LaskyJ.L., PonzioN.M., ThorbeckeG.J.: Characterization and growth factor requirements of SJL lymphomas. I. Development of a B-cell growth factor-dependent in vitro cell line, cRCS-X.J. Immunol., 140: 679–687, 1988.
38.
LaskyJ.L., ThorbeckeG.J.: Characterization and growth factor requirements of SJL lymphomas. II. Interleukin 5-dependence of the in vitro cell line cRCS-X, and influence of other cytokines.Eur. J. Immunol., 19: 365–371, 1989.
LipfordE.H., SmithH.R., PittalugoS., JaffeE.S., SteinbergA.D., CossmanJ.: Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma.J. Clin. Invest., 79: 637–642, 1987.
41.
LukesR.J., TindleB.H.: Immunoblastic lymphadenopathy: a hyperimmune entity resembling Hodgkin's disease.N. Engl. J. Med., 292: 1–8, 1975.
42.
MedeirosJ.L., LardelliP., Stetler-StevensonM., LongoD.L., JaffeE.S.: Genotypic analysis of diffuse, mixed cell lymphomas.Am. J. Clin. Pathol., 95: 547–555, 1991.
43.
MerzH., HoussianF.A., OrscheschekK., RenauldJ.C., FliednerA., HerinM., NoelH., KadinM., Mueller-HermelinkH.K., Van SnichJ., FellerA.C.: Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma.Blood, 78: 1311–1317, 1991.
MurphyE.D.: SJL/J, a new inbred strain of mouse with a high, early incidence of reticulum-cell neoplasms.Proc. Am. Assoc. Cancer Res., 4: 46, 1963.
46.
NakauchiH., OsadaH., YagitaH., OkamuraK.: Molecular evidence that SJL reticulum cell sarcomas are derived from pre-B cell. Clonal rearrangement of heavy chain but not light chain immunoglobulin genes.J. Immunol., 139: 2803–2809, 1987.
NathwaniB.H., RappaportH., MoranE.M., PangalisG.A., KimH.: Evolution of immunoblastic lymphoma in angioimmunoblastic lymphadenopathy.Recent Results Cancer Res., 64: 235–240, 1978.
49.
NewcomS.R., KadinM.E., AnsariA.A.: Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth.Am. J. Pathol., 131: 569–577, 1988.
50.
OhuishiK., BonavidaB.: Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.J. Immunol., 138: 4524–4529, 1987.
51.
OsborneB.M., ButlerJ.J., PughW.C.: The value of immunophenotyping on paraffin sections in the identification of T-cell rich B-cell large-cell lymphomas: lineage confirmed by JH rearrangement.Am. J. Surg. Pathol., 14: 933–938, 1990.
52.
PangalisG.A., MoranE.M., NathwaniB.N., ZelmanR.J., KimH., RappaportH.: Angioimmunoblastic lymphadenopathy: long term follow-up study.Cancer, 52: 318–321, 1983.
53.
PattengaleP.K., TaylorC.R.: Experimental model of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias.Am. J. Pathol., 113: 237–265, 1983.
54.
PonzioN.M., DavidC.S., ShrefflerD.C., ThorbeckeG.J.: Properties of reticulum cell sarcomas of SJL/J mice: V. Nature of reticulum cell sarcoma surface antigen which induces proliferation of normal SJL/J cells.J. Exp. Med., 146: 132–145, 1977.
55.
PonzioN.M., LermanS.P., ChapmanJ.M., ThorbeckeG.J.: Properties of reticulum cell sarcomas in SJL/J mice. IV. Minimal development of cytotoxic cells despite marked proliferation to syngeneic RCS in vivo and in vitro.Cell. Immunol., 32: 10–22, 1977.
56.
PonzioN.M., HayamaT., NaglerC., KatzI.R., HoffmanM.K., GilbertK., VilcekJ., ThorbeckeG.J.: la-restricted interaction of normal lymphoid cells and SJL lymphoma (reticulum cell sarcoma) leading to lymphokine production. II. Rapid production of antibody-enhancing factor, Interleukin 2 and immune interferon.J. Natl. Cancer Inst.72: 311–320, 1984.
57.
PonzioN.M., AlonsoA., AlisauskasR.M.: Dependence of lymphoma growth on « Reversed Immunological Surveillance ». Pathol.Immunopathol. Res., 6: 1–21, 1987.
58.
PonzioN.M., BrownP.H., ThorbeckeG.J.: Host-tumor interactions in the SJL lymphoma model.Int. Rev. Immunol.1: 273–301, 1988.
59.
PopeR.M., CederbaumA.I., LewisW., MannikM.: Immunoblastic lymphadenopathy presenting as respiratory insufficiency.Am. J. Med. Sci., 274: 213–219, 1977.
RosloniecE.F., GottliebC., ButchA.W., LermanS.P.: Comparative growth of SJL/J lymphomas in irradiated and normal SJL/J mice: cell cycle distribution and tumor cell quantification.J. Natl. Cancer Inst., 75: 877–883, 1985.
SeigneurinJ.M., MingatJ., LenoirG.M., CoudercP., MicoudM.: Angioimmunoblastic lymphadenopathy after infectious mononucleosis. Br. Med. J. (Clin.Res. Ed.), 282: 1574–1575, 1981.
64.
ShamotoM., SuchiT.: Intracytoplasmic type A virus-like particles in angioimmunoblastic lymphadenopathy.Cancer, 44: 1641–1643, 1979.
65.
SieglerR., RichM.A.: Pathogenesis of reticulum cell sarcoma in mice.J. Natl. Cancer Inst., 41: 125–143, 1968.
66.
StavnezerJ., LaskyL., PonzioN.M., ScheidM.P., ThorbeckeG.J.: Reticulum cell sarcomas of SJL mice have rearranged immunoglobulin heavy and light chain genes.Eur. J. Immunol., 19: 1063–1069, 1989.
